

НЕМАТОРОІЕТІС Е ЦИРНАТІС ЗЧЯТЕМ -НАЧАТ ВАТСН-

SUBJECT : <u>Pharma</u> LEC NO. : <u>4</u> DONE BY : <u>Abd</u>

و قول المستار المستالة




- 6. Prasugrel: (oral)
 - Increased risk of bleeding (CI: in patients with history of TIA or stroke) bleeding stroke
- Clopidogrel (oral once /day) (preferred to ticlopidine; less risk of neutropenia)
 - Rash Gastric irritation- diarrhea.
 - Clopidogrel is a prodrug → avoid with PPIs e.g. omeprazole
 as it inhibits its activation in liver by CYP450
- 8. Ticagrelor: shortness of breath
- 9. Abciximab (IVI): thrombocytopenia, arrhythmia.

ANTICOAGULANTS

- A. Parenteral Anticoagulants:
- I. <u>Indirect</u> thrombin inhibitors: Heparin low molecular weight heparins (LMWHs) fondaparinux.
- II. Direct thrombin inhibitors: Bivalirudin Argatroban.
- B. Oral anticoagulants: Warfarin New oral anticoagulants (NOAC).

A.PARENTERAL ANTICOAGULANTS



Site of action of Indirect & Direct Thrombin Inhibitors

 → Indirect Thrombin inhibitors: CHepoirin CLUWH Gfondorparinux
 Those form a complex with antithrombin & may work on other factors.
 > Antithrombin is one of indogenous anti-coagulants those are indogenous substances that Keeps blood in it's fluid state.

I. Indirect thrombin inhibitors:

1. Heparin (unfractionated heparin; UFH)

1.) Didn't undergo any processing "taken from it source as it's "

Chemistry

- Sulfated mucopolysaccharide with high MW (HMWH) "High molecular weight heparin"
- Highly acidic with electronegative charge.
- Source: porcine intestinal mucosa and bovine lung *As both sources are animal sources this may "induce allergic reaction"

Pharmacological Actions

1. Anticoagulant action: (effective both in vitro and in vivo)

Mechanism: combines with antithrombin (natural anticoagulant factor)

forming heparin-antithrombin complex which accelerates the inhibitory

effect of antithrombin on activated clotting factors specially:

- Factor IIa (Thrombin) - factor IXa - factor Xa., 192, active

- 2. Slight vasodilator effect \rightarrow canalization of thrombus.
- 3. Plasma-clearing effect by stimulating lipoprotein lipase enzyme.

Pharmacokinetics

- <u>Immediate onset of action after IV injection and short duration (4-6 h).</u>
- 80 % metabolized in the liver by heparinase enzyme.
- 20 % excreted unchanged via the kidney.
- Does not cross placenta & is not secreted in milk (high MW) → can be used during pregnancy (if clearly indicated) or lactation.

Routes of Administration & Doses

- **IV bolus** (5,000 IU), followed by **IV infusion** (1,000 IU/h); guided by aPTT).
- SC: 5,000 IU (low dose of heparin) for prophylaxis, 2 hours preoperative and every 12 hours postoperative for 5-7 days.

Heparin should not be given by IMI as hematoma can occur.

4) bleeding under the skin

 → Note that: for a drug to optimally absorped it must be both water
 & Lipid soluble.
 Heparin doesn't follow this role as it's highly ionized "poor oral absorption".
 Heparin must be given parenthaly Control of Therapy Jused to monitor the unpredictable kinetics & dynamics

aPTT (activated partial thromboplastin time): should **Not** > 2-2.5 normal • value (normal value 30-35 seconds).

Adverse Effects

- 1. Hemorrhage.
- 2. Hair loss (alopecia). un Known mechanism (reversible)
- 3. <u>Hematoma if given by IMI</u>. As it's anticoargulant needle puncture will cause constant bleeding
- 4. Hypersensitivity. As #\$ for non -human-SOURCE
- 5. **Hyperkalemia** (monitor K level if heparin is given > 7 days) 2^{ry} to aldosterone deficiency (due to inhibition of an enzyme necessary for (Angiostensin) aldosterone synthesis OR² block of Åg-II receptors in suprarenal cortex) "bone weakness"
- 6. Osteoporosis (on long term use, specially in pregnancy).
- 7. Heparin-induced thrombocytopenia (HIT): (regular platelet count is Decrease

required):

- a) Early: mild due to direct effect on platelets.
- b) Late: severe due to immunoglobulin-induced platelet aggregation. in some cases heparin may cause thrombus so you have to

ttt: Replace heparin by direct thrombin inhibitor or fondaparinux A The way it reacts in the body is unpredictable it doesn't alway work in the most ideal way mostly via SC route

8. Unpredictable pharmacokinetic & pharmacodynamic properties: (because

it binds to plasma proteins, macrophages, platelets or endothelial cells) 2) As the amounts of hepanin binding to these blood components varys blwn people

Reversal of Heparin toxicity

- Stop Heparin Fresh blood transfusion As coagulation foctors still working,
- Give heparin antidote: Protamine sulfate chemical antergonism,
 - Highly basic with low MW carrying electropositive charge.
 - Neutralizes heparin (each 1 mg neutralizes \approx 100 IU heparin,

Not exceed 50 mg in any 10 min period).

- Avoid overdose \rightarrow Has a slight anticoagulant effect.
- Partially antagonizes Low-Molecular-Weight Heparins.
- Does not antagonize fondaparinux.

Aldostevone is hormone secreted from adrenal gland of Kidneys it causes Nat retention thus 1 blood volume & pressure on the other hand aldosterione deficiency 1 Not in wrine thus K+ 1 in blood

2. Low-Molecular-Weight Heparins (LMWHs):

(Daltep<u>arin</u> - Enoxa<u>parin</u> - Tinzap<u>arin</u>)

- They are <u>fractions of the standard heparin</u> (unfractionated heparin) thus they have a <u>low molecular weight</u>.
- They are mostly given subcutaneously.
- · Mainly renal excretion. good for people with liver diseases »

Mechanism of Action

• They bind to antithrombin increasing its inhibitory effect on factor X_a and to a lesser extent on thrombin (Factor II_a).

Advantages of LMWHs

- 1. Equal efficacy to unfractionated heparin.
- 2. Greater bioavailability from sc sites.
- 3. Long $t_{1/2} \rightarrow$ given subcutaneously once or twice/day.
- 4. Less thrombocytopenia & osteoporosis.
- 5. Less risk of bleeding.
- 6. No need for laboratory monitoring (predictable ph.kinetics & dynamics).

3. Indirect selective inhibitor of factor Xa: Fondaparinux

- Synthetic Pentasaccharide molecule, <u>derivative of heparin</u>
- Binds to antithrombin with \rightarrow efficient inactivation of factor Xa.
- Long $t_{1/2} \rightarrow$ given once daily sc.
- Low risk of HIT
- Used in venous thromboembolism & heparin induced thrombocytopenia.
- Bleeding is the major adverse effect: not antagonized by protamine sulfate.
- Requires less monitoring than heparin (predictable ph.kinetics & dynamics)

II. Parenteral Direct Thrombin Inhibitors: (DTIs)

- Directly bind to thrombin independent of antithrombin → more inhibition of fibrin-bound thrombin.
- Given intravenously and Sc.
- Bleeding is the major adverse effect (NO antidote)
- Used in: Percutaneous intervention (PCI) & Coronary angioplasty
 - Patients with HIT

Argatroban

• Preferred in patients with renal insufficiency (cleared hepatically not renally).

<u>Bivalirudin</u> (hirudin analogue)

• Also inhibits platelet activation.